Submission of New Drug Application (NDA) to FDA for surufatinib for the treatment of pancreatic and extra-pancreatic neuroendocrine tumours

The NDA for this oral angio-immuno kinase inhibitor with a dual mechanism of action, is supported by data from two positive Phase III studies of surufatinib in China (SANET-p1 & SANET-ep2), & from a surufatinib study conducted in the US. Submission to the EMA is planned.

Source:

Biospace Inc.